Published in Control Clin Trials on April 01, 2004
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst (2011) 5.73
Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila) (2008) 3.99
Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2009) 2.06
Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer Prevention Trial. Int J Cancer (2009) 1.56
Does Finasteride Affect the Severity of Prostate Cancer? A Causal Sensitivity Analysis. J Am Stat Assoc (2008) 1.10
Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev (2010) 0.98
Chemoprevention of prostate cancer: Natural compounds, antiandrogens, and antioxidants - In vivo evidence. J Carcinog (2011) 0.97
Hormones and prostate carcinogenesis: Androgens and estrogens. J Carcinog (2011) 0.86
A perspective on the role of estrogen in hormone-induced prostate carcinogenesis. Cancer Lett (2012) 0.85
Statin drug use is not associated with prostate cancer risk in men who are regularly screened. J Urol (2014) 0.83
Factors associated with adherence to an end-of-study biopsy: lessons from the prostate cancer prevention trial (SWOG-Coordinated Intergroup Study S9217). Cancer Epidemiol Biomarkers Prev (2014) 0.82
Prospective study of human herpesvirus type 8 serostatus and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial. Cancer Causes Control (2014) 0.77
Prospective study of cytomegalovirus serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial. Cancer Causes Control (2012) 0.77
Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical Trials. J Clin Oncol (2016) 0.76
Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program. Semin Oncol (2015) 0.75
The influence of finasteride on the development of prostate cancer. N Engl J Med (2003) 24.45
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med (2004) 15.10
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med (2003) 11.35
International staging system for multiple myeloma. J Clin Oncol (2005) 11.29
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst (2013) 10.30
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2006) 9.91
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst (2005) 7.70
Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med (2013) 7.53
Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA (2006) 7.20
Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol (2007) 6.73
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA (2005) 6.50
American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin (2010) 6.45
Erectile dysfunction and subsequent cardiovascular disease. JAMA (2005) 6.22
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med (2013) 6.17
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol (2008) 6.11
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila) (2010) 5.81
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst (2011) 5.73
Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst (2009) 5.62
Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA (2013) 5.56
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet (2011) 5.21
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol (2008) 5.11
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64
Integrating the predictiveness of a marker with its performance as a classifier. Am J Epidemiol (2007) 4.59
Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2006) 4.02
Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila) (2008) 3.99
Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol (2006) 3.81
The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol (2007) 3.78
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst (2006) 3.63
Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst (2006) 3.62
The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol (2009) 3.34
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst (2005) 2.99
Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol (2007) 2.97
The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg (2009) 2.96
Estimated impact of the Prostate Cancer Prevention Trial on population mortality. Cancer (2005) 2.91
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol (2008) 2.64
Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol (2011) 2.57
Prospective evaluation of operating characteristics of prostate cancer detection biomarkers. J Urol (2010) 2.54
Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710. Cancer (2014) 2.48
Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res (Phila) (2008) 2.43
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem (2007) 2.38
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev (2010) 2.36
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol (2013) 2.29
Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J Urol (2007) 2.24
Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol (2005) 2.24
Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem (2007) 2.23
Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. J Clin Oncol (2005) 2.19
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol (2014) 2.19
Pharmacological approaches to reducing the risk of prostate cancer. Eur Urol (2009) 2.09
Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol (2002) 2.07
Predicting risk of prostate cancer in men receiving finasteride: effect of prostate volume, number of biopsy cores, and American Urological Association symptom score. Urology (2013) 2.06
Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2009) 2.06
External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology (2006) 2.05